Development of the Next Generation Influenza Vaccine

Marc-André D’Aoust
Vice-President, Research and Innovation
Medicago, inc

Current influenza vaccination provides only a limited protection against the dominant virus subtype H3N2. Medicago has developed a recombinant seasonal influenza vaccine in the form of virus-like particles (VLPs) that is currently evaluated in a human efficacy study involving 10,000 subjects. The plant-based technology allows for the production of vaccines that match the circulating strains and the VLP display of antigens results in strong immune responses.

The presentation will summarize the development of our next generation influenza vaccine, emphasising on the technological platform and (pre-) clinical results.

4th Oct, 14.00, DAGZ-Seminar-room, Muthgasse 18, 4th floor

Hosted by
Herta Steinkellner
Richard Strasser
Alexandra Castilho